DE825869T1 - Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten - Google Patents
Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhaltenInfo
- Publication number
- DE825869T1 DE825869T1 DE0825869T DE96914505T DE825869T1 DE 825869 T1 DE825869 T1 DE 825869T1 DE 0825869 T DE0825869 T DE 0825869T DE 96914505 T DE96914505 T DE 96914505T DE 825869 T1 DE825869 T1 DE 825869T1
- Authority
- DE
- Germany
- Prior art keywords
- lactobacillus plantarum
- pharmaceutical composition
- composition according
- strain
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract 10
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract 10
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 10
- 239000004475 Arginine Substances 0.000 title claims abstract 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract 5
- 206010070545 Bacterial translocation Diseases 0.000 claims abstract 4
- 206010067125 Liver injury Diseases 0.000 claims abstract 4
- 241000124008 Mammalia Species 0.000 claims abstract 4
- 230000007375 bacterial translocation Effects 0.000 claims abstract 4
- 206010019663 Hepatic failure Diseases 0.000 claims abstract 3
- 238000009109 curative therapy Methods 0.000 claims abstract 3
- 231100000753 hepatic injury Toxicity 0.000 claims abstract 3
- 231100000835 liver failure Toxicity 0.000 claims abstract 3
- 208000007903 liver failure Diseases 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract 2
- 241000282412 Homo Species 0.000 claims 3
- 235000009697 arginine Nutrition 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 231100000439 acute liver injury Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (10)
1. Pharmazeutische Zusammensetzung, umfassend
- einen Lactobacillus plantarum-Stamm, mit der Fähigkeit menschliche Darmschleimhaut
in vivo zu bevölkern;
- Arginin; und
- einen pharmazeutisch verträglichen Träger.
2. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Lactobacillus
plantarum-Stamm ein Adhäsin hat, welches Haftfähigkeit an einen Rezeptor auf menschlichen Darmepithelzellen vermittelt.
3. Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, wobei der Lactobacillus-Stamm
ein Lactobacillus plantarum-Stamm ist, der zu einer Gruppe gehört,
welche eine Restriktionsendonuklease-Analyseähnlichkeit von mehr als 70% zu einem Lactobacillus plantarum 299 Stamm, Hinterlegungsnummer DSM 6595,
hat, unter Verwendung des Pearson Produktmomentkorrelationskoeffizienten (engl.: Pearson product moment correlation coefficient) und des ungewichteten
Paargruppenalgorithmusses mit arithmetischen Durchschnitten (UPGMA; GelCompare 3.0, Applied Maths, Kortrijk, Belgien).
4. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei
der Lactobacillus plantarum-Stamm aus der Gruppe, bestehend aus Lactobacillus plantarum 299, DSM 6595, und Lactobacillus plantarum 299v, DSM 9843, ausgewählt
ist.
5. Pharmazeutische Zusammenstzung nach einem der Ansprüche 1 bis 4, wobei das
Arginin L-Arginin ist.
6. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 5 zur oralen
oder rektalen Verabreichung.
7. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 6 zur Behandlung
von akuter Leberverletzung und Leberversagen und damit verbundener bakterieller Translokation in Säugern einschließlich des Menschen.
8. Verfahren zur heilenden und/oder prophylaktischen Behandlung von Leberverletzung
und Leberversagen und damit verbundener bakterieller Translokation in Säugern einschließlich des Menschen, umfassend die Verabreichung einer therapeutisch
wirksamen Dosis einer pharmazeutischen Zusammensetzung gemäß einem der Ansprüche 1 bis 6.
9. Zusammensetzung, umfassend eine Kombination eines Stammes von Lactobacillus
plantarum und Arginin zum Therapiegebrauch.
10. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 bis 6 und 9 in
der Herstellung eines Medikamentes für die heilende und/oder prophylaktische
Behandlung von Leberverletzung und Leberversagen und damit verbundener bakterieller Translokation in Säugern einschließlich des Menschen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501719A SE9501719D0 (sv) | 1995-05-09 | 1995-05-09 | Pharmaceutical composition |
| PCT/SE1996/000603 WO1996035440A1 (en) | 1995-05-09 | 1996-05-08 | Pharmaceutical composition comprising lactobacillus plantarum and arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE825869T1 true DE825869T1 (de) | 1998-07-16 |
Family
ID=20398250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0825869T Pending DE825869T1 (de) | 1995-05-09 | 1996-05-08 | Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten |
| DE69622855T Expired - Fee Related DE69622855T2 (de) | 1995-05-09 | 1996-05-08 | Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69622855T Expired - Fee Related DE69622855T2 (de) | 1995-05-09 | 1996-05-08 | Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0825869B1 (de) |
| JP (1) | JP4058560B2 (de) |
| KR (1) | KR19990008403A (de) |
| CN (1) | CN1152678C (de) |
| AT (1) | ATE221783T1 (de) |
| AU (1) | AU704886B2 (de) |
| BR (1) | BR9608284A (de) |
| CA (1) | CA2220498A1 (de) |
| DE (2) | DE825869T1 (de) |
| EE (1) | EE03597B1 (de) |
| ES (1) | ES2112818T3 (de) |
| GR (1) | GR980300028T1 (de) |
| NO (1) | NO317668B1 (de) |
| PL (1) | PL184603B1 (de) |
| SE (1) | SE9501719D0 (de) |
| WO (1) | WO1996035440A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100376954B1 (ko) * | 1995-07-31 | 2003-07-18 | 프로비 에이비 | 장에서집락화하는유산간균 |
| EP1276488B1 (de) | 2000-03-24 | 2006-12-20 | Societe Des Produits Nestle S.A. | Milchsäurebakterium zur prävention der bauchfellentzündung |
| KR100585391B1 (ko) * | 2002-01-24 | 2006-06-01 | 주식회사 프로바이오닉 | 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물 억제 활성을 갖는 신규 락토바실러스 프란타럼 Probio-38 및 이를 함유하는 생균활성제 |
| SE527555C2 (sv) * | 2003-04-04 | 2006-04-11 | Probi Ab | Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar |
| US20070224285A1 (en) * | 2004-03-31 | 2007-09-27 | Calpis Co., Ltd | Agent for Preventing or Suppressing Hepatopathy and Functional Food for Preventing or Suppressing Hepatopathy |
| KR100592717B1 (ko) * | 2004-11-20 | 2006-06-26 | 주식회사 알엔에이 | 간 손상 보호 및 예방에 유용한 활성을 갖는 조성물 |
| CN1322111C (zh) * | 2004-12-17 | 2007-06-20 | 上海交大昂立股份有限公司 | 一种植物乳杆菌 |
| CN100337653C (zh) * | 2004-12-21 | 2007-09-19 | 上海交大昂立股份有限公司 | 一种含有植物乳杆菌的组合物 |
| EP1931363B1 (de) * | 2005-09-28 | 2015-11-18 | Nordisk Rebalance A/S | Behandlung von entzündlicher darmerkrankung mit probiotischen bakterien und fermentierten cerealien als behandlungseffektoren |
| JP5413819B2 (ja) * | 2008-02-08 | 2014-02-12 | 国立大学法人広島大学 | 肝機能改善剤およびその製造用ツール、ならびにこれらの利用 |
| KR101075558B1 (ko) * | 2008-12-03 | 2011-10-20 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| WO2010064434A1 (ja) * | 2008-12-03 | 2010-06-10 | 国立大学法人広島大学 | 肝機能障害予防剤 |
| KR101075557B1 (ko) | 2008-12-03 | 2011-10-20 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| KR101255050B1 (ko) | 2009-07-14 | 2013-04-16 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| KR101486999B1 (ko) | 2009-07-22 | 2015-01-28 | 씨제이제일제당 주식회사 | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| CN102618456B (zh) * | 2012-02-28 | 2013-08-21 | 江南大学 | 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途 |
| TWI463986B (zh) * | 2012-08-29 | 2014-12-11 | Univ China Medical | 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途 |
| WO2018195067A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| WO2023104887A1 (en) * | 2021-12-09 | 2023-06-15 | Société des Produits Nestlé S.A. | Lactobacillus acidophilus to increase agmatine production by microbiota |
-
1995
- 1995-05-09 SE SE9501719A patent/SE9501719D0/xx unknown
-
1996
- 1996-05-08 EE EE9700269A patent/EE03597B1/xx not_active IP Right Cessation
- 1996-05-08 BR BR9608284A patent/BR9608284A/pt not_active IP Right Cessation
- 1996-05-08 WO PCT/SE1996/000603 patent/WO1996035440A1/en not_active Ceased
- 1996-05-08 PL PL96323320A patent/PL184603B1/pl not_active IP Right Cessation
- 1996-05-08 ES ES96914505T patent/ES2112818T3/es not_active Expired - Lifetime
- 1996-05-08 DE DE0825869T patent/DE825869T1/de active Pending
- 1996-05-08 CN CNB961953993A patent/CN1152678C/zh not_active Expired - Fee Related
- 1996-05-08 CA CA002220498A patent/CA2220498A1/en not_active Abandoned
- 1996-05-08 AU AU57846/96A patent/AU704886B2/en not_active Ceased
- 1996-05-08 DE DE69622855T patent/DE69622855T2/de not_active Expired - Fee Related
- 1996-05-08 KR KR1019970707930A patent/KR19990008403A/ko not_active Withdrawn
- 1996-05-08 EP EP96914505A patent/EP0825869B1/de not_active Expired - Lifetime
- 1996-05-08 JP JP53399796A patent/JP4058560B2/ja not_active Expired - Fee Related
- 1996-05-08 AT AT96914505T patent/ATE221783T1/de not_active IP Right Cessation
-
1997
- 1997-11-07 NO NO19975136A patent/NO317668B1/no not_active Application Discontinuation
-
1998
- 1998-04-30 GR GR980300028T patent/GR980300028T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2112818T1 (es) | 1998-04-16 |
| NO975136L (no) | 1997-11-07 |
| PL323320A1 (en) | 1998-03-16 |
| AU704886B2 (en) | 1999-05-06 |
| JP4058560B2 (ja) | 2008-03-12 |
| GR980300028T1 (en) | 1998-04-30 |
| KR19990008403A (ko) | 1999-01-25 |
| SE9501719D0 (sv) | 1995-05-09 |
| DE69622855T2 (de) | 2003-04-10 |
| EE03597B1 (et) | 2002-02-15 |
| EP0825869B1 (de) | 2002-08-07 |
| BR9608284A (pt) | 1999-06-08 |
| ATE221783T1 (de) | 2002-08-15 |
| DE69622855D1 (de) | 2002-09-12 |
| CN1190346A (zh) | 1998-08-12 |
| EE9700269A (et) | 1998-04-15 |
| NO317668B1 (no) | 2004-11-29 |
| CA2220498A1 (en) | 1996-11-14 |
| CN1152678C (zh) | 2004-06-09 |
| JPH11504936A (ja) | 1999-05-11 |
| PL184603B1 (pl) | 2002-11-29 |
| NO975136D0 (no) | 1997-11-07 |
| AU5784696A (en) | 1996-11-29 |
| ES2112818T3 (es) | 2003-02-16 |
| EP0825869A1 (de) | 1998-03-04 |
| WO1996035440A1 (en) | 1996-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE825869T1 (de) | Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten | |
| Tauxe et al. | Antimicrobial resistance of Shigella isolates in the USA: the importance of international travelers | |
| McCulloch et al. | Randomized controlled trial of doxycycline in prevention of recurrent periodontitis in high‐risk patients: antimicrobial activity and collagenase inhibition | |
| Wunderlich et al. | Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea | |
| Stone et al. | The incidence of regurgitation during cardiopulmonary resuscitation: a comparison between the bag valve mask and laryngeal mask airway | |
| Jacobsen et al. | Occupational health problems and adverse patient reactions in orthodontics | |
| Ohrui | Preventive strategies for aspiration pneumonia in elderly disabled persons | |
| US20090324563A1 (en) | Moisturizer | |
| ATE231885T1 (de) | Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura | |
| NO931085L (no) | Tarmkanal-koloniserende lactobasiller | |
| NZ599302A (en) | Preventing diseases in infants delivered via caesarean section | |
| RU93057876A (ru) | Применение штамма гриба fusarium в качестве продуцента и препарат на его основе, обладающий адаптогенным и иммуномодулирующим действием | |
| KR970065708A (ko) | 박테리아 균주와 이와 같은 균주를 함유하는 의약 조성물 및 변형된 담즙산대사에 의해 야기되거나 관련된 질병의 예방 및 치료용으로서의 그의 용도 | |
| Tricarico et al. | Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate | |
| CA2120062A1 (en) | Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy | |
| Laplanche et al. | Exposure to vinyl chloride monomer: results of a cohort study after a seven year follow up. The French VCM Group. | |
| WO1997028812A3 (en) | Pharmaceutical compositions for biological treatment of infections by enterococcus faecium strains resistant to antibiotics and to vancomycin in particular (vre) | |
| CA2159485A1 (en) | Anti-oxydant alkylaryl polyether alcohol polymers | |
| Done et al. | Therapy of acute rheumatic fever | |
| Messini et al. | Bacteremia after dental treatment in mentally handicapped people | |
| EP4527454A3 (de) | Verfahren zur behandlung von morbus fabry bei patienten mit einer mutation im gla-gen | |
| Woods | Pyogenic dental infections: A ten year review | |
| Jolliffe | Newer Knowledge of the Vitamin B-Complex | |
| NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
| Shaw et al. | Adherence and Invasion of Aeromonas Caviae to Monolayer Cells: Adherence and Invasion of Aeromonas caviae |